A First in Man Study of MABp1 in Patients With Advanced Cancers

Inclusion Criteria

• •pathologically confirmed advanced malignancy that is metastatic or unresectable and which is refractory to standard therapy or for which thee is no standard therapy that provides benefits for \>/= 3 months
• •measurable or non-measurable disease at baseline
• •at least 4 weeks since the last dose of chemotherapy, radiation therapy, immunotherapy, or surgery; at least 6 weeks for therapy which is known to have delayed toxicity; at least 4 weeks since treatment with biologic/targeted therapies; at least 2 weeks since last hormonal therapy
• •will not be treated with any other chemotherapy, immunotherapy, radiotherapy or investigational drug while enrolled on this protocol
• •age \>/= 18 year, male or female
• •Eastern Cooperative Oncology Group performance status 0,1,or 2
• •Serum potassium and magnesium levels within institutional normal limits. Total serum calcium or ionized calcium level must be greater than or equal to the low limit of normal.
• •Adequate renal function, defined by serum creating \</= 1.5 x ULN
• •Adequate hepatic function
• •Adequate bone marrow function WOCBP, a negative serum pregnancy test result at screening.
• •WOCBP or men whose sexual partners are WOCBP who are willing to use an acceptable method of contraception for at least 1 month prior to study entry, for the duration of the study, and for at least 3 months after the last dose of study medication
• •Signed and dated IRB approved ICF before any protocol specific screening procedures are performed